Dose-dependent pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine
نویسندگان
چکیده
منابع مشابه
Pulmonary dysfunction in transfusion-dependent patients with thalassemia major.
Pulmonary function tests were performed on 62 transfusion-dependent patients with thalassemia major, ranging in age from 8 to 33 years, and receiving chelation therapy with desferrioxamine or deferiprone. Percent predicted values for FVC, FEV1, and PEF were significantly reduced, whereas FEV1/FVC and maximal expiratory flow at 25% FVC were within normal limits, indicating a restrictive disease....
متن کاملHearing loss in Iranian thalassemia major patients treated with deferoxamine: A systematic review and meta-analysis
Background: Hearing disorders are reported in thalassemia patients treated with deferoxamine. This study aimed to assess hearing loss in Iranian thalassemia major patients treated with deferoxamine. Methods: This review article was designed based on PRISMA guidelines. To review the literature, two researchers studied national and international databases including Iranmedex, Magiran, Medlib, SI...
متن کاملRegression of cardiac insufficiency after ambulatory intravenous deferoxamine in thalassemia major.
A case of severe cardiac failure due to iron overload in a patient with beta-thalassemia major is reported. The patient was successfully treated with high-dose ambulatory intravenous deferoxamine (desferrioxamine). This type of chelation appears to be a valuable alternative to subcutaneous deferoxamine administration in the presence of severe iron overload.
متن کاملEVALUATION OF PULMONARY IRON OVER LOAD IN PATIENTS WITH Β-THALASSEMIA MAJOR USING SPIROMETRY
Background & Aims: Spirometry changes in thalassemic patients can be obstructive or restrictive and pulmonary dysfunction depends on age and body iron overload. In this study the effectiveness of lung spirometry in detecting iron overload in patients with β-thalassemia was investigated. Materials & Methods: This cross-sectional (descriptive-analytic) study investigated the spirometry test resu...
متن کاملThe Comparison of Efficacy of Original Brand Deferoxamine with Generic Iranian Made Deferoxamine in Urinary Iron Excretion in Patients with Thalassemia Major
Background: Deferoxamine mesylate is still the conventional and well-known iron chelator for patients with thalassemia major. However, due to some marketing issues the well-known original brand, Desferal®, produced by Novartis Pharmaceuticals Company is not as available as before. The generic brands of Deferoxamine have been introduced in many parts of the world including Iran; however, they ar...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Hematology
سال: 1998
ISSN: 0361-8609,1096-8652
DOI: 10.1002/(sici)1096-8652(199808)58:4<340::aid-ajh18>3.0.co;2-b